Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases

American Journal of Neuroradiology

Volumn 39, Issue 5, 2014, Pages 920-927

  Tan, W L ^a   Huang, W Y ^a   Yin, B ^a   Xiong, J ^a   Wu, J S ^a   Geng, Daoying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE SCANNER; RETROSPECTIVE STUDY; CANCER GRADING; CONTROLLED STUDY; DIFFUSION COEFFICIENT; MIDDLE AGED; NEUROIMAGING; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SEX RATIO; WORLD HEALTH ORGANIZATION; BRAIN TUMOR; COMPUTER ASSISTED DIAGNOSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ISOCITRATE DEHYDROGENASE 1; GENETIC MARKER; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; DIFFUSION TENSOR IMAGING; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84901050755     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3803     Document Type: Article

References (34)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
3. Nikiforova MN, Hamilton RL. Molecular diagnostics of gliomas. Arch Pathol Lab Med 2011;135:558-68
4. Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009;68:1319-25
5. Capper D, Sahm F, Hartmann C, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010;34:1199-204
6. Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. NeuroOncol 2012;108:403-10
7. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269-73
8. Loussouarn D, Le Loupp AG, Frenel JS, et al. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 2012;40:2058-62
9. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719-29
10. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44
11. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34
12. Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2012;131:766-68
13. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624-29
14. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro Oncol 2012;107:197-205
15. Khayal IS, Vandenberg SR, Smith KJ, et al. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. NeuroOncol 2011;13:1192-201
16. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109
17. Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011;28:115-23
18. Khalid L, Carone M, Dumrongpisutikul N, et al. Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol 2012;33:852-57
19. Brander A, Kataja A, Saastamoinen A, et al. Diffusion tensor imaging of the brain in a healthy adult population: normative values and measurement reproducibility at 3 T and 1.5 T. Acta Radiol 2010;51:800-07
20. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-07
21. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003;4:469-80
22. Jenkinson MD, Smith TS, Brodbelt AR, et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405-12
23. Beppu T, Inoue T, Shibata Y, et al. Measurement of fractional anisotropy using diffusion tensor MRI in supratentorial astrocytic tumors. J NeuroOncol 2003;63:109-16
24. Mikkelsen T. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 2010;32:788-95
25. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261-65
26. Liu Y, Jiang W, Liu J, et al. IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma. J Neurooncol 2012;109:253-60
27. Graham DI, Lantos PL. Greenfield's Neuropathology. London: Hodder Arnold Publisher; 2002:767-1052
28. Jolapara M, Patro SN, Kesavadas C, et al. Can diffusion tensor metrics help in preoperative grading of diffusely infiltrating astrocytomas? A retrospective study of 36 cases. Neuroradiology 2011;53:63-68
29. Byrnes TJ, Barrick TR, Bell BA, et al. Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo. NMR Biomed. 2011;24:54-60
30. Jakab A, Molnár P, Emri M, et al. Glioma grade assessment by using histogram analysis of diffusion tensor imaging-derived maps. Neuroradiology 2011;53:483-91
31. Zou QG, Xu HB, Liu F, et al. In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging. Clin Radiol 2011;66:953-60
32. Gupta R, Webb-Myers R, Flanagan S, et al. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011;64:835-44
33. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245-54
34. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469-74